Specialty Dosage Drugs

Inhaled Niclosamide Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2

February 24, 2022

TFF Pharmaceuticals announces findings that inhaled niclosamide significantly inhibits viral replication of the Omicron variant of SARS-CoV-2.

Considerations for DPIs and MDIs in Inhalation Drug Delivery

October 15, 2021

Experts share best practices in designing, manufacturing, and scaling up dry powder inhaler and metered dose inhaler drug–device combination products for inhalation drug delivery.

Understanding Combination Product Regulations

September 16, 2021

Considering interactions and understanding regulatory requirements are crucial when developing a drug or biologic product for use with a medical device.

SAHPRA Authorizes ImmunityBio to Proceed with Trial of T-Cell Vaccine as Booster Against COVID-19

July 16, 2021

ImmunityBio will proceed with a Phase I/II/III trial in South Africa of their dual-antigen T-cell vaccine as a boost in participants who were previously vaccinated against COVID-19.

Combining Multiparticulates and 3DP for Patient-Centric Dosage Forms

May 03, 2021

Aprecia and Glatt investigate manufacturing technologies to widen the formulation design space for oral delivery.

Nanoform and Aprecia Explore 3D-Printed Drug Dosage Forms

April 21, 2021

The collaboration will evaluate Nanoform’s fast dissolution nanoparticles in Aprecia’s ZipDose 3DP technology platform for buccal and oral drug delivery.

Balancing the Art and Science of Topical Drug Formulation

April 03, 2021

Topical drugs are attractive to patients, but these complex products pose challenges for formulators.

Packaging Delivers Micro Dose

March 15, 2021

Smart packaging opens doors to new products for diagnosis and treatment of eye problems.

Manufacturing Drug–Device Combination Products

September 03, 2020

A device manufacturing process must be carefully designed in the early stages of development to ensure success in commercial manufacturing.

Inovio to Scale-Up Manufacture of Intradermal Delivery Device for its COVID-19 Vaccine

June 24, 2020

Inovio received a $71-million contract from the US Department of Defense to scale up manufacture of its Cellectra smart device to deliver its DNA vaccine.